secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001558370-23-019011
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics Q3 net loss $4.7M; Phase 1 trial of GT-02287 underway
-----------------------------------------------------------------------

- Net loss $4.7M ($0.37/sh) vs $4.6M ($0.38/sh) in Q3 2022; R&D expense rose $0.4M to $2.4M.
- Cash, cash equivalents and marketable securities $12.3M; sufficient into Q3 2024.
- Phase 1 clinical trial of GT-02287 initiated in Australia; dose escalation ongoing.
- Completion of single ascending dose part expected late Q4 2023/early Q1 2024; multiple ascending dose expected Q2 2024.
- Preclinical data presented at Parkinson's congress showed GT-02287 reduced NfL biomarker and motor dysfunction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000155837023019011/0001558370-23-019011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000155837023019011/ganx-20231114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer